TL;DR: Aetna, a CVS Health company, modified CPB 0557 governing cancer vaccines, effective December 4, 2025. Every cancer vaccine category addressed in this policy is classified as experimental, investigational, or unproven — meaning your cancer vaccine billing faces a blanket non-coverage wall under this policy.
This update to CPB 0557 in the Aetna system doesn't open new coverage doors. It reinforces and refines Aetna's position that cancer vaccines — across more than a dozen tumor types and multiple vaccine modalities — lack sufficient clinical evidence to support reimbursement. If your practice or health system bills for any investigational cancer vaccine therapy under ICD-10 codes in the C00.0–C96.9 malignant neoplasm range or D00.00–D09.9 carcinoma in situ range, this policy directly affects your claim outcomes.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Cancer Vaccines — CPB 0557 |
| Policy Code | CPB 0557 |
| Change Type | Modified |
| Effective Date | December 4, 2025 |
| Impact Level | High |
| Specialties Affected | Oncology, hematology/oncology, gynecologic oncology, head and neck surgery, radiation oncology, surgical oncology |
| Key Action | Audit any pending or submitted cancer vaccine claims against Aetna's non-coverage list before submitting, and update your denial management workflow to account for this policy |
Aetna Cancer Vaccine Coverage Criteria and Medical Necessity Requirements 2025
The Aetna cancer vaccine coverage policy under CPB 0557 is stark: there are no covered indications. Every cancer vaccine addressed in this policy bulletin fails Aetna's medical necessity standard.
That's not hedging. Aetna's position is that the clinical evidence is not sufficient to draw conclusions about health outcomes for any of the cancer vaccine approaches listed. When a payer says that, it means one thing for your billing team — expect denial.
If you're asking whether Aetna prior authorization requirements apply here, the practical answer is that prior authorization is irrelevant when the underlying service is categorically non-covered. Submitting a prior auth request for an experimental service doesn't convert it into a covered benefit. You're not getting a medical necessity determination — you're getting a denial regardless of the documentation.
The coverage policy spans both tumor-type-based exclusions and modality-based exclusions. Aetna evaluates both the cancer type being treated and the specific vaccine approach. Your claim can fail on either axis.
Aetna Cancer Vaccine Exclusions and Non-Covered Indications
This is where CPB 0557 does its real work. Aetna lists specific vaccine types and specific cancer indications as experimental, investigational, or unproven. Every item on this list is a denial waiting to happen.
Specific Vaccine Types Excluded
Aetna explicitly names six vaccine modalities as non-covered under CPB 0557:
1. Helper multi-peptide (6MHP) vaccine for metastatic melanoma.
This affects melanoma-focused practices. If a patient presents with metastatic melanoma and receives 6MHP, Aetna will not cover it.
2. HLA-A24-binding peptide vaccines for gastric cancer.
This is a narrow exclusion targeting a specific peptide-binding approach for gastric malignancies.
3. Melanoma vaccine — also known as Theraccine or Oncophage vaccine — for any indication.
Note the "for any indication" language. There is no off-label workaround here. Theraccine and Oncophage are excluded in full, regardless of the diagnosis code you attach.
4. p16(INK4a)-based peptide vaccine for HPV-associated cancers.
This covers a broad set of tumor sites — anal, cervical, oropharyngeal, penile, rectal, vaginal, and vulvar cancers. If your practice sees HPV-associated malignancies, this exclusion applies to a wide patient population.
5. p62 DNA vaccine (Elenagen) for solid tumors.
Elenagen is excluded across breast, kidney, lung, and ovarian cancers, as well as melanoma. That's five tumor types in one line item.
6. Whole cancer stem cell-based vaccines as adjuvant therapy for surgical management of solid tumors.
This one matters for surgical oncology teams. If a patient undergoes solid tumor resection and a stem cell-based vaccine is part of the adjuvant plan, Aetna won't cover it.
Cancer Types Where Vaccine Therapy Is Non-Covered
Beyond specific vaccine products, Aetna also excludes tumor-associated antigenic peptide-based vaccine therapy across a long list of cancer types. The policy explicitly notes this is not an all-inclusive list — which means Aetna may deny cancer vaccine claims for tumor types not listed here as well.
The explicitly named cancer types are:
| # | Excluded Procedure |
|---|---|
| 1 | Acute myeloid leukemia |
| 2 | Breast cancer |
| 3 | Central nervous system cancers, including glioblastoma and neuroblastoma |
| 4 | Colorectal cancer |
| 5 | Gallbladder cancer |
| 6 | Gastric cancer |
| 7 | Glioma |
| 8 | Head and neck cancer |
| 9 | Hepatic cancer |
| 10 | Lung cancer |
| 11 | Oral squamous cell carcinoma |
| 12 | Ovarian cancer |
| 13 | Pancreatic cancer |
That's 13 named cancer types. Combined with the six specific vaccine modalities above, CPB 0557 covers an enormous swath of oncology billing. If your payer mix includes a meaningful percentage of Aetna patients with any of these diagnoses, this policy affects your revenue cycle.
The real issue here is that phrase "not an all-inclusive list." Aetna is reserving the right to deny cancer vaccine claims for tumor types not named above. Your billing team should not assume that a tumor type's absence from this list means coverage is available.
Coverage Indications at a Glance
| Indication | Status | Relevant ICD-10 Codes | Notes |
|---|---|---|---|
| 6MHP vaccine — metastatic melanoma | Experimental / Not Covered | C43.xx (malignant melanoma) within C00.0–C96.9 | Specific vaccine type excluded |
| HLA-A24 peptide vaccine — gastric cancer | Experimental / Not Covered | C16.x within C00.0–C96.9 | Specific modality excluded |
| Theraccine / Oncophage (melanoma vaccine) — any indication | Experimental / Not Covered | C00.0–C96.9, D00.00–D09.9 | "Any indication" language — no exceptions |
| p16(INK4a) peptide vaccine — HPV-associated cancers (anal, cervical, oropharyngeal, penile, rectal, vaginal, vulvar) | Experimental / Not Covered | C00.0–C96.9 (site-specific codes) | Broad exclusion across HPV-associated tumor sites |
| p62 DNA vaccine (Elenagen) — solid tumors (breast, kidney, lung, ovary, melanoma) | Experimental / Not Covered | C00.0–C96.9 (site-specific codes) | Five tumor types named explicitly |
| Whole cancer stem cell-based vaccine — adjuvant to solid tumor surgery | Experimental / Not Covered | C00.0–C96.9 | Applies in surgical adjuvant context |
| Tumor-associated antigenic peptide-based vaccines — AML, breast, CNS cancers, colorectal, gallbladder, gastric, glioma, head and neck, hepatic, lung, oral SCC, ovarian, pancreatic | Experimental / Not Covered | C00.0–C96.9, D00.00–D09.9 | Non-exhaustive list — other tumor types may also be denied |
| Cancer vaccine therapy — any indication not listed above | Likely Not Covered | C00.0–C96.9, D00.00–D09.9 | "Not all-inclusive" language puts unlisted indications at denial risk |
Aetna Cancer Vaccine Billing Guidelines and Action Items 2025
This policy has been in effect since December 4, 2025. If you haven't updated your workflows yet, do it now.
| # | Action Item |
|---|---|
| 1 | Audit all outstanding cancer vaccine claims submitted to Aetna after December 4, 2025. Pull claims with ICD-10 codes in the C00.0–C96.9 or D00.00–D09.9 ranges that involve any vaccine-related procedure. Flag any that overlap with the named vaccine types or cancer indications in CPB 0557. |
| 2 | Update your denial management queues to expect rejections on cancer vaccine billing. Train your AR team to recognize these denials as policy-driven, not documentation-driven. Additional clinical notes will not reverse a categorical experimental designation. |
| 3 | Do not submit prior authorization requests for services covered by this exclusion list. Prior authorization processes exist for covered services where medical necessity is in question. For categorically non-covered services, you're not going to get an approval — and the process wastes time your team doesn't have. |
| 4 | Update your patient financial counseling process for Aetna patients pursuing cancer vaccine therapy. If a physician recommends a vaccine listed in CPB 0557, your team should inform the patient before treatment that Aetna will not cover this service. Get a signed patient financial responsibility agreement before the service is rendered. This protects your practice and sets appropriate expectations. |
| 5 | Watch the "not an all-inclusive list" language carefully. If a cancer vaccine claim falls outside the named indications but gets denied, document Aetna's stated rationale. CPB 0557 is the controlling policy — reference it explicitly in any appeal, and pull the December 4, 2025 effective date into your appeal language. |
| 6 | If your practice participates in cancer vaccine clinical trials, consult your compliance officer. Trial-related billing has separate rules — Medicare has specific clinical trial billing provisions, and commercial payers like Aetna handle trial services differently from standard of care. Don't assume CPB 0557 controls your trial billing without getting a second set of eyes on it. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cancer Vaccines Under CPB 0557
CPB 0557 does not list specific CPT or HCPCS procedure codes. This is worth noting for your cancer vaccine billing workflow — Aetna's exclusions in this policy are defined by vaccine type and cancer indication, not by procedure code. That means your team can't simply scrub claims against a code list. You need to review the clinical service itself against the policy's indication-level criteria.
Key ICD-10-CM Diagnosis Codes
These are the diagnosis code ranges Aetna associates with CPB 0557. Any claim in these ranges that involves a cancer vaccine service is subject to this policy.
| Code / Range | Description |
|---|---|
| C00.0 – C96.9 | Malignant neoplasms |
| D00.00 – D09.9 | Carcinoma in situ |
| Z23 | Encounter for immunization |
The Z23 code — encounter for immunization — is the one that can create unexpected exposure. If your billing team uses Z23 as a secondary or primary code on any cancer vaccine encounter, Aetna will cross-reference CPB 0557. Make sure your coders understand that Z23 in an oncology context doesn't change the non-coverage outcome.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.